These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Current views on the pathogenesis and pharmacotherapy of Parkinson disease]. Kostowski W Neurol Neurochir Pol; 1987; 21(6):541-7. PubMed ID: 2835696 [No Abstract] [Full Text] [Related]
44. Alterations in dopamine receptors: effect of lesion and haloperidol treatment. Goldstein M; Lew JY; Asano T; Ueta K Commun Psychopharmacol; 1980; 4(1):21-5. PubMed ID: 6105037 [No Abstract] [Full Text] [Related]
45. [Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)]. Ohmoto T; Miyamoto T; Baba Y No To Shinkei; 1977 Jul; 29(7):?31-40. PubMed ID: 409419 [No Abstract] [Full Text] [Related]
54. Bromocriptine in Parkinsonism. Calne DB; Teychenne PF; Claveria LE; Eastman R; Greenacre JK; Petrie A Br Med J; 1974 Nov; 4(5942):442-4. PubMed ID: 4425916 [TBL] [Abstract][Full Text] [Related]
55. Depletion of dopamine in the striatum as an experimental model of Parkinsonism: direct effects and adaptive mechanisms. Schultz W Prog Neurobiol; 1982; 18(2-3):121-66. PubMed ID: 6813911 [No Abstract] [Full Text] [Related]
56. Ergot alkaloids and cyclic nucleotides in the CNS. Trabucchi M; Hofmann M; Montefusco O; Spano PF Pharmacology; 1978; 16 Suppl 1():150-55. PubMed ID: 205889 [TBL] [Abstract][Full Text] [Related]